Business Wire

Secure Code Warrior and Okta Collaborate to Create New Solution to Secure Developer Workflows

2.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Secure Code Warrior, the global, developer-driven security leader, today announced an exciting addition to the Okta Integration Network. Okta, the leading independent provider of identity, and Secure Code Warrior collaborated to deliver a new solution - the Secure Code Warrior (SCW) Connector for Okta Workflows, which enables organizations and developers to write secure code from the start of the software development lifecycle (SDLC).

Applying a security-first mindset, organizations can design an identity workflow that protects builds from the beginning of the life cycle, giving organizations the flexibility to only provide GitHub repo access to security proficient developers. This helps organizations promote a security first culture while the SCW Learning Platform enables developers to meet these standards and requirements. Organizations have implemented this solution across their application, security and engineering teams to provide this additional layer of security.

Preventing insecure code and ensuring better access control during software development remains a significant need for industries across all verticals. Meanwhile, developers recognize the importance of delivering secure software applications but face competing priorities. According to SCW’s recently released “The State of Developer-Driven Security Survey, 2022”, 67% knowingly left vulnerabilities and exploits in their code, with a lack of time and a cohesive approach cited as the two main barriers to the adoption of secure coding practices.

“This new solution will help organizations reduce the risk of developers committing insecure code by ensuring that employees are up to date on the latest vulnerabilities and secure coding techniques. Through our work together with Okta on a security proficiency check, AppSec Managers can be confident that the team is committing secure code without moving developers out of their workflow. Now, leaders can focus on broad strategic efforts to improve the organization’s security posture without sacrificing quality or time.” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior.

“Okta Workflows provides a no-code, low-code approach to automating identity-centric processes at scale. As an early adopter of Workflows Connector Builder, we are excited to have the new Secure Code Warrior connector in the Okta Integration Network, which goes beyond SSO and provisioning to support advanced integration flows. Developers can be confident that their secure code knowledge is up to date and relevant to the code they are committing” said David Shackelford, Senior Director, Okta.

The Secure Code Warrior Connector for Okta Workflows utilizes key components of both companies’ technology platforms to benefit organizations and developers alike:

  • Pre-configured actions enable developer teams to quickly build the desired workflows in a no-code/low code environment, without the hassle of getting into the complexities of API calls.
  • Once the workflow is ready, it will run automatically and can be customized for frequency.
  • Secure Code Warrior’s Learning Platform provides information on the developers’ assessment score and course completion status, giving teams the insights to determine their security skills when writing code.
  • Organizations have the flexibility to only allow GitHub repo access to security proficient developers

Creating and automating secure developer workflows is now easier than ever thanks to this new industry solution from Secure Code Warrior and Okta. The Secure Code Warrior Connector for Okta Workflows is available at https://help.okta.com/wf/en-us/Content/Topics/Workflows/connector-reference/securecodewarrior/securecodewarrior.htm.

To learn more, visit www.securecodewarrior.com/blog/scw-connector-for-okta-workflows.

About Secure Code Warrior
Secure Code Warrior builds a culture of security-driven developers by giving them the skills to code securely. Our flagship Learning Platform delivers relevant skills-based pathways, hands-on missions, and contextual tools for developers to rapidly learn, build, and apply their skills to write secure code at speed. Established in 2015, Secure Code Warrior has become a critical component for over 450 enterprises including leading financial services, retail, and global technology companies across the world. Visit: www.securecodewarrior.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Carolina Machado
+61 452 265 033
cmachado@securecodewarrior.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye